Literature DB >> 6144343

The actions of antipsychotic drugs on dopamine receptors in the rat substantia nigra.

R D Pinnock.   

Abstract

The activity of neurones in the zona compacta of the rat substantia nigra was recorded extracellularly in vitro. Dopamine produced a dose-dependent depression of firing, threshold doses being in the 3 microM range. The inhibitory effects of dopamine were antagonized by (-)-sulpiride (pA2 7.5), haloperidol (pA2 8.4) and cis-flupenthixol (pA2 6.9). The actions of gamma-aminobutyric acid (GABA) were not affected by these compounds. The gradients of Schild plots of data for (-)-sulpiride were less than unity while those for haloperidol and cis-flupenthixol were greater than unity, which suggests that the antagonism was not competitive. This is discussed with regard to the use of a bioassay system in the analysis of the effects of antagonists. Haloperidol and (-)-sulpiride were found to have similar potencies, as dopamine receptor antagonists, to those predicted from biochemical and clinical efficacy studies, but cis-flupenthixol was less potent than expected.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144343      PMCID: PMC1986915          DOI: 10.1111/j.1476-5381.1984.tb16128.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Antipsychotic drug doses and neuroleptic/dopamine receptors.

Authors:  P Seeman; T Lee; M Chau-Wong; K Wong
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

2.  Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy.

Authors:  J A Norman; A H Drummond; P Moser
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

3.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

4.  Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro.

Authors:  J Hyttel
Journal:  Life Sci       Date:  1978-08-14       Impact factor: 5.037

5.  Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.

Authors:  B S Bunney; J R Walters; R H Roth; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

6.  A simple perfusion chamber for the study of nervous tissue slices in vitro.

Authors:  H L Haas; B Schaerer; M Vosmansky
Journal:  J Neurosci Methods       Date:  1979-12       Impact factor: 2.390

7.  Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists.

Authors:  J Lehmann; M Briley; S Z Langer
Journal:  Eur J Pharmacol       Date:  1983-03-18       Impact factor: 4.432

8.  Dopamine receptor blocking activity of sulpiride in the central nervous system.

Authors:  F Honda; Y Satoh; K Shimomura; H Satoh; H Noguchi; S Uchida; R Kato
Journal:  Jpn J Pharmacol       Date:  1977-06

9.  Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations.

Authors:  A E Theodorou; M D Hall; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1980-06       Impact factor: 3.765

10.  Antidromic identification of dopaminergic and other output neurons of the rat substantia nigra.

Authors:  P G Guyenet; G K Aghajanian
Journal:  Brain Res       Date:  1978-07-07       Impact factor: 3.252

View more
  9 in total

1.  Effect of BHT 920 on monoaminergic neurons of the rat brain: an electrophysiological in vivo and in vitro study.

Authors:  V Seutin; J Scuvée-Moreau; I Giesbers; L Massotte; A Dresse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

2.  Responses of rat substantia nigra compacta neurones to L-DOPA.

Authors:  N B Mercuri; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

3.  Endogenous dopamine modifies electroresponsiveness of pars compacta cells in the guinea pig substantia nigra in vitro.

Authors:  R Kapoor; C Webb; S A Greenfield
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  The mechanism of amphetamine-induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro.

Authors:  N B Mercuri; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

5.  Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions.

Authors:  Y Wang; R Xu; T Sasaoka; S Tonegawa; M P Kung; E B Sankoorikal
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

6.  Electrophysiological effects of amineptine on neurones of the rat substantia nigra pars compacta: evidence for an inhibition of the dopamine uptake system.

Authors:  N B Mercuri; F Stratta; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

7.  Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Authors:  Matteo Marti; Flora Mela; Carlo Veronesi; Remo Guerrini; Severo Salvadori; Mauro Federici; Nicola B Mercuri; Anna Rizzi; Gianfranco Franchi; Lorenzo Beani; Clementina Bianchi; Michele Morari
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

8.  Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area.

Authors:  B Bowery; L A Rothwell; G R Seabrook
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

9.  Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta.

Authors:  M G Lacey; N B Mercuri; R A North
Journal:  J Physiol       Date:  1987-11       Impact factor: 5.182

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.